7:01AM Agenus announces its Agenus' QS-21 Stimulon Adjuvant Selected for Biodefense Program (AGEN) 0.79 : Co announces a license agreement with Integrated BioTherapeutics for the use of the QS-21 Stimulon adjuvant in the development of a vaccine against Ebola and Marburg viruses1. Under this agreement, co is entitled to receive a license fee, program-based milestone payments and worldwide royalties on net sales of the vaccine product. QS-21 is currently being evaluated in ~15 vaccine candidates.
Market Data 
Markets 
AI
